INDICATIONS

WEZLANA is indicated for the treatment of:

  • patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • patients 6 years or older with active psoriatic arthritis...Read more
  • adult patients with moderately to severely active Crohn’s disease.
  • adult patients with moderately to severely active ulcerative colitis.
  • patients 6 years or older with moderate to severe plaque psoriasis who are candidates...Read more for phototherapy or systemic therapy.
  • patients 6 years or older with active psoriatic arthritis.
  • adult patients with moderately to severely active Crohn’s disease.
  • adult patients with moderately to severely active ulcerative colitis.

Already have a prescription?
Enroll in the WEZLANA Co-Pay Program*

The WEZLANA Co-Pay Program may help eligible patients with commercial insurance (usually self-purchased or through an employer) lower their out-of-pocket costs for WEZLANA.

  • Pay as little as $0* out-of-pocket for each dose
  • Can be applied to deductible, co-insurance, and co-payment*
  • Support available regardless of income level

*Only for commercially insured patients. Eligibility criteria and program maximums apply. See full Terms and Conditions.

WEZLANA is distributed by Nuvaila™, and the WEZLANA Co-Pay Program is administered by Amgen SupportPlus.

Sample WEZLANA™ (ustekinumab-auub) co-pay card

For eligible commercially insured patients who received WEZLANA via infusion and received a balance due from their healthcare provider, you may use this form to request reimbursement.

All fields are required to confirm eligibility and complete enrollment.

Insurance information

What kind of insurance do you use to pay for your WEZLANA prescription? (select one below)

Are you eligible for Medicare but receive prescription drug coverage from a former employer, union, or welfare plan?

Unfortunately, you are not eligible to enroll in the WEZLANA Co-Pay Program. You may find the resources below helpful.

By clicking the links below you will be leaving the WEZLANA.com website.

By checking this box, I agree that I read, understand, and accept the Terms and Conditions of the WEZLANA Co-Pay Card.

Unfortunately, you are not eligible to enroll in the WEZLANA Co-Pay Program. You may find the resources below helpful.

By clicking the links below you will be leaving the WEZLANA.com website.

Unfortunately, you are not eligible to enroll in the WEZLANA Co-Pay Program.

Please scroll to the bottom of this page to accept

SUMMARY OF TERMS AND CONDITIONS

It is important that every patient read and understand the full Amgen* SupportPlus Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

As further described below, in general:

  • The Amgen SupportPlus Co-Pay Card is open to patients with commercial insurance that covers an Amgen SupportPlus product, regardless of financial need. The program is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash paying patients or where prohibited by law. (See ELIGIBILITY section in full Terms & Conditions.)
  • The Amgen SupportPlus Co-Pay Card may help lower your Amgen SupportPlus product out-of-pocket medication costs. Out-of-pocket costs may include co-payment, co-insurance, and deductible out-of-pocket costs. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of the product. The Amgen SupportPlus Co-Pay Card provides support up to the Maximum Program Benefit or Patient Total Program Benefit. If a patient's commercial insurance plan imposes different or additional requirements on patients who receive Amgen SupportPlus Co-Pay Card benefits, Amgen has the right to modify or eliminate those benefits. Whether you are eligible to receive the Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Amgen SupportPlus Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card, whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). (See PROGRAM BENEFITS section in full Terms & Conditions.)
  • Amgen SupportPlus patient may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle of the Amgen SupportPlus product.
  • Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit. Please ask your Amgen SupportPlus Support Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card by calling 1-833-44AMGEN (1-833-442-6436). (See PROGRAM DETAILS section in full Terms & Conditions.)
  • See PROGRAM DETAILS section in full Terms & Conditions.

I. ELIGIBILITY

*Eligibility Criteria: Subject to program limitations and terms and conditions, the Amgen SupportPlus Co-Pay Card is open to patients who have been prescribed an Amgen SupportPlus product and who have commercial or private insurance that covers an Amgen SupportPlus product, including state and federal plans commonly referred to as “healthcare exchanges plans”. This program helps eligible patients cover out-of-pocket medication costs related to an Amgen SupportPlus product, up to program limits. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product. There is no income requirement to participate in this program.

This offer is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for an Amgen SupportPlus product or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Amgen SupportPlus product prescription. This offer is only valid in the United States, Puerto Rico, and the US territories.

II. PROGRAM BENEFITS

The Amgen SupportPlus Co-Pay Card may modify the benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM)) requires enrollment in the Amgen SupportPlus Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact Amgen SupportPlus Support at 1-833-44AMGEN (1-833-442-6436). Health plans and Pharmacy Benefit Managers are prohibited from enrolling or assisting in the enrollment of patients in the Amgen SupportPlus Co-Pay Card. The patient, or his/her legal representative, must personally enroll in the Amgen SupportPlus Co-Pay Card in order to be eligible for program benefits.

If at any time a patient begins receiving coverage for medications under any federal, state, or government healthcare program (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and you must contact Amgen SupportPlus at 1-833-44AMGEN (1-833-442-6436) (Monday through Friday, from 8:00 am to 8:00 pm ET) to stop your participation in this program.

Patients may not seek reimbursement for the value received from the Amgen SupportPlus Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Amgen SupportPlus Co-Pay Card of your insurance carrier or pharmacy benefit manager. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

III. PROGRAM DETAILS

For all eligible patients the Amgen SupportPlus Co-Pay Card offers:

  • A program benefit that covers the patient's eligible out-of-pocket medication costs for the Amgen SupportPlus product (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Program Benefit determined by the program per calendar year. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product.
  • Amgen SupportPlus patients may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle.
  • Amgen will pay the remaining eligible out-of-pocket prescription costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit.

Maximum Program Benefit, Patient Total Program Benefit, Benefits May Change, End or Vary Without Notice: The program provides up to a Maximum Program Benefit of assistance to reduce a patient’s out-of-pocket medication costs that Amgen will provide per patient for each calendar year, which must be applied to the Amgen SupportPlus patient’s out-of-pocket costs (co-pay, deductible, or co-insurance and annual out-of-pocket maximum). Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Program Benefit. The Patient Total Program Benefit may be less than the Maximum Program Benefit, depending on the terms of a patient’s plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your Amgen SupportPlus Support Representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). Participating patients are solely responsible for updating Amgen with changes to their insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Amgen SupportPlus Co-Pay Card benefits to reduce a patient’s out-of-pocket costs, such as accumulator adjustment benefit design or a co-pay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility.

Patients may use the card every time they receive a prescription fill, dose or cycle of the Amgen SupportPlus product, up to the Maximum Program Benefit or Patient Total Program Benefits reset each calendar year. Re-enrollment in the program is required at regular intervals. Patients may continue in the program as long as patient re-enrolls as required by Amgen and continues to meet all of the program’s eligibility requirements during participation in the program. Patients can enroll/reenroll by calling 1-833-44AMGEN (1-833-442-6436).

Here is your WEZLANA Co-Pay card! Save your card details and make sure you provide the information to your Specialty Pharmacy.

Don’t miss the call from the Specialty Pharmacy! Your Specialty Pharmacy will be calling to arrange delivery. Save them as a contact in your phone. If you do not connect with the Specialty Pharmacy, your WEZLANA will not be delivered.

WEZLANA Co-Pay Card

RxBIN: XXXXXX

PCN: XXXX

Group: XXXXXXXXXX

Member ID: XXXXXXXXXXX

Here is your WEZLANA Co-Pay card! Save your card details and make sure you provide the information to your Specialty Pharmacy.

Don’t miss the call from the Specialty Pharmacy! Your Specialty Pharmacy will be calling to arrange delivery. Save them as a contact in your phone. If you do not connect with the Specialty Pharmacy, your WEZLANA will not be delivered.

Add us to your contacts

Simply scan this code with your phone’s camera and save our call center's contact information to your contacts for your convenience.

Contact us at 1-866-269-4471. Our team is ready to help Monday – Friday from 8 AM to 8 PM ET.

Please try again, or contact us at 1-866-269-4471 so we can further assist you. Our team is ready to help Monday – Friday from 8 AM to 8 PM ET.

IMPORTANT SAFETY INFORMATION

WEZLANA™ (ustekinumab-auub) is a prescription medicine that affects your immune system. WEZLANA can increase your chance of having serious side effects including:

Serious Infections

WEZLANA may lower your ability to fight infections and may increase your risk of infections. While taking ustekinumab products, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

  • Your doctor should check you for TB before starting WEZLANA and watch you closely for signs and symptoms of TB during treatment with WEZLANA.
  • If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with WEZLANA.

You should not start taking WEZLANA if you have any kind of infection unless your doctor says it is okay.

Before starting WEZLANA, tell your doctor if you:

  • think you have an infection or have symptoms of an infection such as:
    • fever, sweats, or chills
    • muscle aches
    • cough
    • shortness of breath
    • blood in phlegm
    • weight loss
    • warm, red, or painful skin or sores on your body
    • diarrhea or stomach pain
    • burning when you urinate or urinate more often than normal
    • feel very tired
  • are being treated for an infection or have any open cuts.
  • get a lot of infections or have infections that keep coming back.
  • have TB, or have been in close contact with someone with TB.

After starting WEZLANA, call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. WEZLANA can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take WEZLANA may also be more likely to get these infections.

Cancers

WEZLANA may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving WEZLANA. Tell your doctor if you have any new skin growths.

Posterior Reversible Encephalopathy Syndrome (PRES)

PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious Allergic Reactions

Serious allergic reactions can occur. Stop using WEZLANA and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Lung Inflammation

Cases of lung inflammation have happened in some people who receive ustekinumab products and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn’t go away during treatment with WEZLANA.

Before receiving WEZLANA, tell your doctor about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed above for serious infections, cancers, or PRES.
  • ever had an allergic reaction to ustekinumab products or any of its ingredients. Ask your doctor if you are not sure.
  • have recently received or are scheduled to receive an immunization (vaccine). People who take WEZLANA should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receiving WEZLANA or one year after you stop receiving WEZLANA.
  • have any new or changing lesions within psoriasis areas or on normal skin.
  • are receiving or have received allergy shots, especially for serious allergic reactions.
  • receive or have received phototherapy for your psoriasis.
  • are pregnant or plan to become pregnant. It is not known if WEZLANA can harm your unborn baby. You and your doctor should decide if you will receive WEZLANA.
  • are breastfeeding or plan to breastfeed. WEZLANA can pass into your breast milk.
  • talk to your doctor about the best way to feed your baby if you receive WEZLANA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed WEZLANA:

  • Use WEZLANA exactly as your doctor tells you to.
  • WEZLANA is intended for use under the guidance and supervision of your doctor. In children 6 years and older, it is recommended that WEZLANA be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of WEZLANA at home, you should receive training on the right way to prepare and inject WEZLANA. Your doctor will determine the right dose of WEZLANA for you, the amount for each injection, and how often you should receive it. Do not try to inject WEZLANA yourself until you or your caregiver have been shown how to inject WEZLANA by your doctor or nurse.

Common side effects of WEZLANA include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with WEZLANA. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the accompanying WEZLANA full Prescribing Information, including Medication Guide.

WHAT IS WEZLANA (ustekinumab-auub)?

WEZLANA is a prescription medicine used to treat:

  • adults and children 6 years and older with moderate to severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
  • adults and children 6 years and older with active psoriatic arthritis.
  • adults 18 years and older with moderately to severely active Crohn’s disease.
  • adults 18 years and older with moderately to severely active ulcerative colitis.

IMPORTANT SAFETY INFORMATION

WEZLANA™ (ustekinumab-auub) is a prescription medicine that affects your immune system. WEZLANA can increase your chance of having serious side effects including:

STELARA® is a registered trademark of Janssen Biotech, Inc.

WEZLANA is a trademark of Amgen Inc.

WEZLANA is distributed by Nuvaila™.